Chips Ahoy Recall Issued After Consumers Gag On “Solidified” Ingredient

Following reports of consumers gagging or choking on certain Chewy Chips Ahoy cookies, a recall has been issued due to a risk that the products may contain “solidified” ingredients that pose a serious health risk, especially for young children.

The FDA announced the Chewy Chips Ahoy recall on April 13, following several problems where consumers found large, solid pieces of cornstarch in the cookies, which reportedly caused them to choke or gag, or resulted in dental injuries. The extent of those injuries was not made clear by either the FDA or the manufacturer, Mondelēz Global LLC.

The manufacturer has identified a certain production range of the cookies that may contain an unexpected solidified ingredient, because the cornstarch failed to fully incorporate in the mixing procedure. This caused it to become solid during the baking process.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Mondelēz Global LLC issued a press release (PDF) on April 13 announcing the recall.

“This voluntary recall is being conducted because of the potential for certain product to contain an unexpected solidified ingredient,” the recall notice states. “Some reports of potential adverse health effects have been received.”

As a result of this failure, officials are warning customers to stop eating the recalled products immediately to prevent further injury.

The recall includes 13 ounce packages of Chewy Chips Ahoy cookies that are marked with a “Best When Used By” date of September 7, 8, 14, and 15 of 2019. All impacted products have the UPC code 0 44000 03223 4 on the top left side of the packaging.

Impacted Chips Ahoy products were manufactured by Mondelez Global LLC of Deerfield, Illinois. They were distributed nationwide to retail stores.

Customers with recalled products should stop consuming them immediately and contact Mondelez Global at 1-844-366-1171 to receive additional information regarding the recall.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn
Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn (Posted today)

Lawsuit alleges that Abbott Laboratories failed to provide families and the medical community with adequate warnings about the risks associated with it’s cow’s milk-based Similac formula, which a now adult woman indicates has left her with life-long NEC injuries.

Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects
Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects (Posted yesterday)

Six breast cancer patients have asked a federal judge for permission to amend a complaint filed in March 2024, which describes problems linked to the device and painful side effects experienced when the tissue marker migrated out of position or shattered inside their bodies.

Representative Sample of Suboxone Injury Cases To Be Identified Through Bellwether Process in MDL
Representative Sample of Suboxone Injury Cases To Be Identified Through Bellwether Process in MDL (Posted 2 days ago)

Lawyers involved in Suboxone tooth decay lawsuits will meet with the a federal judge this week, and discuss plans to select a representative group of injury claims that will go through case-specific discovery in preparation for a series of early test trials.